137 results
8-K
FOLD
Amicus Therapeutics Inc
8 Jan 24
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
7:01am
announced, the Company will also be presenting at the 42nd Annual J.P. Morgan Healthcare Conference on January 8th, 2024. A copy of the presentation … Materials – 42nd Annual J.P. Morgan Healthcare Conference
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Signature Page
8-K
EX-99.2
FOLD
Amicus Therapeutics Inc
8 Jan 24
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
7:01am
Exhibit 99.2
AT THE FOREFRONT OF THERAPIES FOR RARE DISEASES 42nd Annual J.P. Morgan Healthcare Conference January 8, 2024
2 Forward-Looking … Disease Harnessing AI to improve diagnosis of people living with Fabry and predicting patient outcomes Partnership with OM1 and leading healthcare
8-K
EX-99.1
ig8oq4 nhlrv5
8 Jan 24
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
7:01am
S-3ASR
yqia2fwmx
8 Nov 23
Automatic shelf registration
5:25pm
8-K
EX-10.1
q2n9gkb
2 Oct 23
Entry into a Material Definitive Agreement
8:48am
8-K
EX-99.1
21yo9y5
21 Aug 23
Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer
7:01am
8-K
qxo3c
15 Aug 23
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
7:00am
8-K
EX-99.1
s703z4 snnm
15 Aug 23
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
7:00am
8-K
EX-99.1
ry2auiy36te4hz5j4sp
8 Aug 23
Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates
7:00am
8-K
EX-99.1
ukv5vfilpode6
27 Jun 23
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union
7:01am
8-K
0zl6h8af
1 Aug 22
Departure of Directors or Certain Officers
5:10pm